Compare Stocks: BNTC, RXRX, SNDX, and ANAB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$56.28	$58.55	$11.40 ▼ $72.36	$1.67B	0.72	366,661 shs	358,263 shs
BNTC Benitec Biopharma	$12.47	$12.73	$9.85 ▼ $16.76	$428.34M	0.28	189,840 shs	103,167 shs
RXRX Recursion Pharmaceuticals	$3.34	$3.32	$2.77 ▼ $7.18	$1.79B	1.03	15.42 million shs	10.54 million shs
SNDX Syndax Pharmaceuticals	$19.54	$20.93	$12.99 ▼ $25.59	$1.73B	0.4	1.32 million shs	1.04 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	0.00%	-2.53%	+5.47%	+5.91%	+176.83%
BNTC Benitec Biopharma	0.00%	-7.49%	+6.49%	+15.25%	-5.82%
RXRX Recursion Pharmaceuticals	0.00%	-4.57%	+11.33%	-11.87%	-28.94%
SNDX Syndax Pharmaceuticals	0.00%	-0.56%	+2.57%	+3.66%	+19.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$56.28	$58.55	$11.40 ▼ $72.36	$1.67B	0.72	366,661 shs	358,263 shs
BNTC Benitec Biopharma	$12.47	$12.73	$9.85 ▼ $16.76	$428.34M	0.28	189,840 shs	103,167 shs
RXRX Recursion Pharmaceuticals	$3.34	$3.32	$2.77 ▼ $7.18	$1.79B	1.03	15.42 million shs	10.54 million shs
SNDX Syndax Pharmaceuticals	$19.54	$20.93	$12.99 ▼ $25.59	$1.73B	0.4	1.32 million shs	1.04 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	0.00%	-2.53%	+5.47%	+5.91%	+176.83%
BNTC Benitec Biopharma	0.00%	-7.49%	+6.49%	+15.25%	-5.82%
RXRX Recursion Pharmaceuticals	0.00%	-4.57%	+11.33%	-11.87%	-28.94%
SNDX Syndax Pharmaceuticals	0.00%	-0.56%	+2.57%	+3.66%	+19.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.64	Moderate Buy	$80.00	42.15% Upside
BNTC Benitec Biopharma	2.60	Moderate Buy	$24.80	98.88% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.06	141.32% Upside
SNDX Syndax Pharmaceuticals	2.85	Moderate Buy	$41.55	112.62% Upside

Current Analyst Ratings Breakdown

Latest BNTC, RXRX, SNDX, and ANAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	ANAB AnaptysBio	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/25/2026	ANAB AnaptysBio	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$75.00 ➝ $70.00
8/25/2026	ANAB AnaptysBio	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold	$70.00
8/24/2026	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00
8/21/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$37.00 ➝ $33.00
8/17/2026	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.30
8/11/2026	SNDX Syndax Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$44.00 ➝ $40.00
8/7/2026	ANAB AnaptysBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/5/2026	SNDX Syndax Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $38.00

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$234.60M	7.10	N/A	N/A	$1.34 per share	42.00
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	$3.71 per share	N/A
RXRX Recursion Pharmaceuticals	$74.68M	23.94	N/A	N/A	$2.14 per share	1.56
SNDX Syndax Pharmaceuticals	$172.35M	10.05	N/A	N/A	$0.74 per share	26.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	-$1.08	N/A	18.95	N/A	-11.53%	N/A	-7.75%	8/31/2026 (Estimated)
BNTC Benitec Biopharma	-$37.92M	-$1.14	N/A	N/A	N/A	N/A	-34.82%	-34.11%	9/28/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.04	N/A	N/A	N/A	-945.94%	-50.41%	-38.25%	11/4/2026 (Estimated)
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.51	N/A	N/A	N/A	-87.52%	-372.94%	-39.11%	11/2/2026 (Estimated)

Latest BNTC, RXRX, SNDX, and ANAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/28/2026	Q4 2026	BNTC Benitec Biopharma	-$0.26	N/A	N/A	N/A	N/A	N/A
8/31/2026	Q2 2026	ANAB AnaptysBio	-$0.4133	N/A	N/A	N/A	$6.67 million	N/A
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million
8/4/2026	Q2 2026	SNDX Syndax Pharmaceuticals	-$0.4477	-$0.55	-$0.1023	-$0.55	$79.36 million	$72.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
BNTC Benitec Biopharma	N/A	56.82	56.82
RXRX Recursion Pharmaceuticals	0.01	5.03	5.03
SNDX Syndax Pharmaceuticals	38.95	6.77	6.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
BNTC Benitec Biopharma	52.19%
RXRX Recursion Pharmaceuticals	89.06%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
BNTC Benitec Biopharma	4.80%
RXRX Recursion Pharmaceuticals	6.65%
SNDX Syndax Pharmaceuticals	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.61 million	20.28 million	Optionable
BNTC Benitec Biopharma	20	34.35 million	32.71 million	No Data
RXRX Recursion Pharmaceuticals	400	535.34 million	499.74 million	Optionable
SNDX Syndax Pharmaceuticals	110	88.61 million	84.36 million	Optionable

BNTC, RXRX, SNDX, and ANAB Headlines

Recent News About These Companies

Man Group plc Takes $4.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX

1 hour ago | marketbeat.com

Bank of New York Mellon Corp Makes New $22.74 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX

3 hours ago | marketbeat.com

Palo Alto Investors LP Acquires Shares of 864,986 Syndax Pharmaceuticals, Inc. $SNDX

August 28 at 6:31 AM | marketbeat.com

Deutsche Bank AG Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX

August 28 at 3:37 AM | marketbeat.com

BlackRock Inc. Makes New Investment in Syndax Pharmaceuticals, Inc. $SNDX

August 28 at 3:28 AM | marketbeat.com

Seven Fleet Capital Management LP Invests $1.65 Million in Syndax Pharmaceuticals, Inc. $SNDX

August 27, 2026 | marketbeat.com

Ieq Capital LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX

August 27, 2026 | marketbeat.com

Trails Edge Capital Partners LP Buys Shares of 1,110,000 Syndax Pharmaceuticals, Inc. $SNDX

August 26, 2026 | marketbeat.com

Elmind Capital LP Buys Shares of 1,855,000 Syndax Pharmaceuticals, Inc. $SNDX

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX

August 25, 2026 | marketbeat.com

Algert Global LLC Has $22.98 Million Holdings in Syndax Pharmaceuticals, Inc. $SNDX

August 25, 2026 | marketbeat.com

Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

August 24, 2026 | invezz.comI

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts

August 20, 2026 | americanbankingnews.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of "Moderate Buy" from Analysts

August 20, 2026 | marketbeat.com

GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX

August 17, 2026 | marketbeat.com

Syndax (SNDX) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $40.00 Price Target at JPMorgan Chase & Co.

August 11, 2026 | marketbeat.com

Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX

August 9, 2026 | marketbeat.com

How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors

August 8, 2026 | finance.yahoo.com

Bank of America Corp DE Decreases Position in Syndax Pharmaceuticals, Inc. $SNDX

August 8, 2026 | marketbeat.com

HC Wainwright Brokers Decrease Earnings Estimates for SNDX

August 7, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC, RXRX, SNDX, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

$56.28 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$56.28 -0.01 (-0.01%)

As of 05:54 AM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Benitec Biopharma NASDAQ:BNTC

$12.47 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$12.48 +0.01 (+0.12%)

As of 03:59 AM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.34 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$3.32 -0.02 (-0.75%)

As of 06:28 AM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Syndax Pharmaceuticals NASDAQ:SNDX

$19.54 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNTC, RXRX, SNDX, and ANAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNTC, RXRX, SNDX, and ANAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNTC, RXRX, SNDX, and ANAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC, RXRX, SNDX, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

Benitec Biopharma NASDAQ:BNTC

Recursion Pharmaceuticals NASDAQ:RXRX

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNTC, RXRX, SNDX, and ANAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNTC, RXRX, SNDX, and ANAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNTC, RXRX, SNDX, and ANAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC, RXRX, SNDX, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

Benitec Biopharma NASDAQ:BNTC

Recursion Pharmaceuticals NASDAQ:RXRX

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools